Nymox's Alzheimer test to be provided in U.K. by Lab 21

By Elaine Rigoli

Tampa, Fla., Feb. 13 - Nymox Pharmaceutical Corp. announced Monday that its AlzheimAlert test will be available in the United Kingdom under an agreement with Lab21 Ltd.

Nymox contends that its AlzheimAlert can aid in the diagnosis of Alzheimer's disease by measuring levels of a brain protein in patients' urine samples. The brain protein, called neural thread protein, is found in higher amounts in the urine of patients suffering from Alzheimer's disease, according to a company release.

Nymox already markets AlzheimAlert in Spain, Greece, Italy and the Czech Republic.

Based in Cambridge, England, Lab21 provides clinical testing service for the pharmaceutical industry and other health care providers throughout the United Kingdom.

Nymox, based in Hasbrouck Heights, N.J., is a biopharmaceutical company specializing in therapeutics and diagnostics development for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.